- £194.74bn
- £213.97bn
- $54.07bn
- 85
- 16
- 87
- 72
Annual balance sheet for AstraZeneca, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 7,992 | 6,398 | 6,405 | 5,962 | 5,654 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5,651 | 8,795 | 9,923 | 11,935 | 13,094 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 19,544 | 26,244 | 22,593 | 25,054 | 25,827 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 8,917 | 10,171 | 9,449 | 10,502 | 11,647 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 66,729 | 105,363 | 96,483 | 101,119 | 104,035 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 20,307 | 22,594 | 26,293 | 30,542 | 27,866 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 51,107 | 66,095 | 59,446 | 61,976 | 63,249 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 15,622 | 39,268 | 37,037 | 39,143 | 40,786 |
| Total Liabilities & Shareholders' Equity | 66,729 | 105,363 | 96,483 | 101,119 | 104,035 |
| Total Common Shares Outstanding |